Royalty Pharma PLC (RPRX)
27.92
+0.04
(+0.13%)
USD |
NASDAQ |
Apr 19, 10:14
Royalty Pharma Debt to Equity Ratio: 0.9401 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.9401 |
| September 30, 2023 | 0.9987 |
| June 30, 2023 | 1.134 |
| March 31, 2023 | 1.196 |
| December 31, 2022 | 1.264 |
| September 30, 2022 | 1.156 |
| June 30, 2022 | 1.179 |
| March 31, 2022 | 1.229 |
| December 31, 2021 | 1.228 |
| Date | Value |
|---|---|
| September 30, 2021 | 1.224 |
| June 30, 2021 | 1.016 |
| March 31, 2021 | 1.192 |
| December 31, 2020 | 1.207 |
| September 30, 2020 | 1.306 |
| June 30, 2020 | 1.422 |
| March 31, 2020 | 1.154 |
| December 31, 2019 | 1.022 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.9401
Minimum
Dec 2023
1.422
Maximum
Jun 2020
1.169
Average
1.192
Median
Mar 2021
Debt to Equity Ratio Benchmarks
| Viatris Inc | 0.8854 |
| Walgreens Boots Alliance Inc | 0.7024 |
| Pacira BioSciences Inc | 0.6004 |
| Amphastar Pharmaceuticals Inc | 0.9227 |
| Maravai LifeSciences Holdings Inc | 1.258 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 16.38B |
| Total Liabilities (Quarterly) | 6.298B |
| Shareholders Equity (Quarterly) | 6.526B |
| Current Ratio | 7.896 |
| Net Debt Paydown Yield | 1.56% |